Cargando…

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis

We sought to evaluate the efficacy of the purine analogue cladribine in 79 patients with advanced systemic mastocytosis (AdvSM) using data from the ‘German Registry on Disorders of Eosinophils and Mast Cells (GREM)’. The overall response rate according to modified Valent criteria (46 evaluable patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lübke, Johannes, Naumann, Nicole, Metzgeroth, Georgia, Kreil, Sebastian, Brand, Timo, Horny, Hans-Peter, Sotlar, Karl, Cross, Nicholas C. P., Fabarius, Alice, Valent, Peter, Hofmann, Wolf-Karsten, Reiter, Andreas, Schwaab, Juliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344834/ https://www.ncbi.nlm.nih.gov/pubmed/37012462 http://dx.doi.org/10.1007/s00277-023-05180-y

Ejemplares similares

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

Functional imaging with dual-energy computed tomography for supplementary non-invasive assessment of mast cell burden in systemic mastocytosis
por: Riffel, Julia, et al.
Publicado: (2022)

An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis
por: Riffel, Philipp, et al.
Publicado: (2020)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort
por: Metzgeroth, Georgia, et al.
Publicado: (2023)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes
por: Valent, Peter, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
por: Jawhar, Mohamad, et al.
Publicado: (2017)

Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy
por: Niedoszytko, Marek, et al.
Publicado: (2021)

Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients
por: Boehm, Thomas, et al.
Publicado: (2019)

Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis
por: Brockow, Knut, et al.
Publicado: (2021)

Protease profile of normal and neoplastic mast cells in the human bone marrow with special emphasis on systemic mastocytosis
por: Atiakshin, Dmitri, et al.
Publicado: (2021)

Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms
por: Rotterdam, Jil, et al.
Publicado: (2021)

ICON: Eosinophil Disorders
por: Valent, Peter, et al.
Publicado: (2012)

Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML
por: Valent, Peter, et al.
Publicado: (2019)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Transcriptomic profiling does not refine mastocytosis diagnosis
por: Buschhorn, Lars, et al.
Publicado: (2023)

Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
por: Kluin-Nelemans, Hanneke C., et al.
Publicado: (2021)

Systemic Mastocytosis: A Rare Case of Increased Liver Stiffness
por: Adolf, Stefanie, et al.
Publicado: (2012)

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
por: Lizak, Nathaniel, et al.
Publicado: (2020)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia
por: Naumann, Nicole, et al.
Publicado: (2022)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

The underestimated role of basophils in Ph(+) chronic myeloid leukaemia
por: Valent, Peter, et al.
Publicado: (2018)

Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR
por: Spiess, Birgit, et al.
Publicado: (2023)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qj2p167bcgfssgml4ipiadk9ei